According to the latest report by IMARC Group, titled "Europe Generic Drug Market Report by Segment (Unbranded Generics, Branded Generics), Therapy Area (Central Nervous System, Cardiovascular, Dermatology, Genitourinary/Hormonal, Respiratory, Rheumatology, Diabetes, Oncology, and Others), Drug Delivery (Oral, Injectables, Dermal/Topical, Inhalers), Distribution Channel (Retail, Hospital), and Country 2025-2033," the Europe generic drug market reached a value of USD 65.1 Billion in 2024. A generic drug is a medication produced to be the same as an already marketed brand-name drug in safety, strength, dosage form, administration route, quality, performance features, and intended use. It works similarly and provides the same clinical advantage as the brand-name medicine. It uses the same active ingredients as brand-name medicines. It may have minor differences from the brand-name product, such as color or different inactive ingredients. It is usually much less expensive than brand-name drugs since the drug producer does not have to duplicate the original clinical trials for checking the effectiveness and safety of the medicine, which reduces the overall cost of introducing the drug to the market.
Europe Generic Drug Market Trends:
The market in Europe is primarily driven by the increasing prevalence of chronic diseases, diabetes and cardiovascular diseases. In line with this, the rising geriatric population and the growing healthcare expenditure are significantly contributing to the market growth. Furthermore, a large number of patent-expired branded drugs and the escalating numbers of clinical trials are positively influencing the market. Apart from this, heavy investments in extensive research and development activities and advancements in drug formulation, such as fixed-dose combination and cost-effective treatment, are expected to augment the market expansion. Moreover, numerous government reimbursement programs have favored lower-cost options, thus accelerating the growth of the generic drug market. Besides, the rapid application of robotic process automation is creating a positive outlook for the market. Additionally, new companies are entering into generic drug manufacturing to capture a significant market share. As a result, they are offering cost-effective and efficient generic versions of branded drugs, thereby supporting the market growth. Looking forward, the market value is projected to reach USD 113.2 Billion by 2033, expanding at a CAGR of 6.3% during 2025-2033.
Market Summary:
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Segment Coverage | Segment, Therapy Area, Drug Delivery, Distribution Channel, Country |
Countries Covered | Germany, France, United Kingdom, Italy, Spain, Others |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
30 N A
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800